✦ LIBER ✦

Prediction of response to treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease

✍ Scribed by Andus, Tilo; Herfarth, Hans; Obermeier, Florian; Kuehbacher, Tanja; Mascheretti, S; Thriene, Wolfgang; Schoelmerich, Juergen; Schreiber, Stefan

Book ID: 124143419
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 164 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)83089-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improvement of arthritis/arthralgia afte

Improvement of arthritis/arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease

✍ Andus, Tilo; Herfarth, Hans; Obermeier, Florian; Kuehbacher, Tanja; Mascheretti, 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Improvement of arthritis and arthralgia

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease

✍ Hans Herfarth; Florian Obermeier; Tilo Andus; Gerhard Rogler; Susanna Nikolaus; 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB

Clinical efficacy of treatment with infl

Clinical efficacy of treatment with infliximab in a german multicenter, prospective, open-label trial in refractory crohn's disease

✍ Schreiber, S.; Kuehbacher, T.; Mascheretti, S.; Hommel, E.; Pohl, C.; Kruis, W.; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Treatment of Crohn’s disease (CD): respo

Treatment of Crohn’s disease (CD): response to Remicade® (infliximab) in the ACCENT I trial through week 54

✍ Paul Rutgeerts; Jean-Frederick Colombel; Stephen Schreiber; Lloyd Mayer; Gary Li 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 39 KB

Efficacy of infliximab in pediatric Croh

Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

✍ Frank M. Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: Infliximab (ifx) is efficacious in inducing remission in severe forms of pediatric crohn's disease (cd). adult studies indicate that ifx is also safe and well tolerated as maintenance therapy. the present study aimed to evaluate in a prospective manner the efficacy and safety of ifx

Open-label infliximab therapy in Crohn's

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

✍ Yago González-Lama; Antonio López-San Román; Ignacio Marín-Jiménez; Begoña Casis 📂 Article 📅 2008 🏛 Elsevier Science 🌐 Spanish ⚖ 98 KB